Feature Channels

Meeting News

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Keywords:

3 San Antonio Studies Target Androgen in Breast Cancer

Breast.Cancer.Pink.jpg

"We're on the cusp of a major revolution in the way we treat breast cancer," says University of Colorado Cancer Center investigator, Jennifer Richer, PhD.

View | Comment

Medicine

Channels:

Keywords:

New Drug Combination for Advanced Breast Cancer Delays Disease Progression

Adelson-Image_YaleNews.jpg

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial.

View | Comment

Medicine

Channels:

Novel Approach for Estrogen-Receptor-Positive Breast Cancer Reported

Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

View | Comment

Medicine

Channels:

Keywords:

Pathway That Degrades Holiday Turkey Fuels Metastasis of Triple Negative Breast Cancer

Turkey.Hands.jpg

University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites.

View | Comment

Medicine

Channels:

Keywords:

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients

A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer.

View | Comment

Medicine

Channels:

Early Trial of New Drug Shows Promise for Patients with Metastatic Triple-Negative Breast Cancer

Nanda-Brown4small_1.jpg

In patients with metastatic triple-negative breast cancer, infusion of pembrolizumab produced durable responses in almost one out of five patients. One of the 27 patients had a complete response and four had a partial response. Seven more patients had stable disease.

View | Comment

Medicine

Channels:

Keywords:

James Ingle, M.D., of Mayo Clinic Recognized for a Career of Contributions to Breast Cancer Research

James Ingle, M.D., an internationally recognized breast cancer expert, will receive the 2014 William L. McGuire Memorial Lecture Award on Dec. 10 at the 2014 San Antonio Breast Cancer Symposium.

View | Comment

Medicine

Channels:

Keywords:

New Resource on Health Threats Posed by Endocrine-disrupting Chemicals Released on Eve of International Chemical Safety Meeting

As governments, industry and public interest groups from across the globe prepare to meet next week to discuss endocrine-disrupting chemicals and other international chemical safety issues, the Endocrine Society and IPEN released a new guide documenting the threat endocrine-disrupting chemicals (EDCs) pose to human health.

View | Comment

Medicine

Channels:

Keywords:

Platinum Agent Combination Treatment for Triple-Negative Breast Cancer Well Tolerated in Phase II Clinical Trial

HirshfieldnoglassesvertNR0814.jpg

Research from Rutgers Cancer Institute of New Jersey shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. The work, which also included genomic profiling to measure molecular correlates of response, is being presented at the San Antonio Breast Cancer Symposium being held this week in Texas.

View | Comment

Medicine

Channels:

Keywords:

Experts in Leukemia and Bone Marrow Transplant Prepare for Upcoming Pivotal Trial of Innovative Targeted Payload Immunotherapy

DraganPhoto.JPG

If approved, Iomab-B should increase the number of patients eligible for curative bone marrow transplant (BMT, also known as HSCT) and improve clinical outcomes.

View | Comment